Abstract
HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
B cell regulation of the anti-tumor response and role in carcinogenesis
Journal for ImmunoTherapy of Cancer Open Access 19 July 2016
-
Involvement of tumor necrosis factor-α in the upregulation of CXCR4 expression in gastric cancer induced by Helicobacter pylori
BMC Cancer Open Access 11 August 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Finzi, D. et al. Latent infection of CD4+ T-cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512–517 (1999).
Kilby, J.M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302–1307 (1998).
Berger, E.A. HIV entry and tropism: the chemokine receptor connection. AIDS 11, S3–16 (1997).
Berger, E.A. et al. A new classification for HIV-1. Nature 391, (1999).
Richman, D.D. & Bozzette, S.A. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 169, 968–974 (1994).
Kimata, J.T. et al. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nature Med. 5, 535–541 (1999).
Simmons, G. et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70, 8355– 8360 (1996).
Choe, H. et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135–1148 (1996).
Perelson, A.S. et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582–1586 (1996).
Cornelissen, M. et al. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J. Virol. 69, 1810–1818 (1995).
Lathey, J.L., Pratt, R.D. & Spector, S.A. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1. J. Infect. Dis. 175, 231–232 (1997).
Trkola, A. et al. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72, 1876– 1885 (1998).
Bleul, C.C. et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94, 1925–1930 (1997).
Grivel, J. & Margolis, L.B. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue. Nature Med. 3, 344–346 (1999).
Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856–1862 (1996).
Michael, N.L. et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta 32. J. Virol. 72, 6040– 6047 (1998).
Zhang, Y. & Moore, J.P. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J. Virol. 73, 3443–3448 (1999).
Michael, N.L. et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nature Med. 3, 338–340 (1997).
Wu, L. et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185, 1681–1691 (1997).
Mosier, D.E. et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73, 3544–3550 (1999).
Gordon, C.J. et al. Enhancement of human immunodeficiency virus type1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion., J. Virol. 73, 684–694 (1999).
Donzella, G.A. et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med. 4, 72– 77 (1998).
Baba, M. et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96, 5698–5703 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Michael, N., Moore, J. HIV-1 entry inhibitors: Evading the issue. Nat Med 5, 740–742 (1999). https://doi.org/10.1038/10462
Issue Date:
DOI: https://doi.org/10.1038/10462
This article is cited by
-
NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology
Cellular & Molecular Immunology (2020)
-
B cell regulation of the anti-tumor response and role in carcinogenesis
Journal for ImmunoTherapy of Cancer (2016)
-
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Cancer Microenvironment (2015)
-
Influence of natural killer cells and perforin-mediated cytolysis on the development of chemically induced lung cancer in A/J mice
Cancer Immunology, Immunotherapy (2014)
-
Genetic Knockouts Suggest a Critical Role for HIV Co-Receptors in Models of HIV gp120-Induced Brain Injury
Journal of Neuroimmune Pharmacology (2012)